Pardhe Bashu Dev, Shakya Shreena, Bhetwal Anjeela, Mathias Jennifer, Khanal Puspa Raj, Pandit Roshan, Shakya Jyotsna, Joshi Hari Om, Marahatta Sujan Babu
Department of Laboratory Medicine, Manmohan Memorial Institute of Health Sciences, Kathmandu, Nepal.
Department of Health Science, National Open College, Sanepa, Lalitpur, Nepal.
BMC Gastroenterol. 2018 Jul 6;18(1):109. doi: 10.1186/s12876-018-0843-6.
Non-alcoholic fatty liver disease (NAFLD) is mutually and bidirectionally linked with metabolic syndrome (MetS) of which it is both the cause and the consequences. Worldwide, 6.3 to 33% of the general populations are estimated to suffer from the disease with even higher prevalence in the group sharing metabolic co-morbidities. Hence, this study aims to recognize various risk factors including metabolic components and blood parameters to predict the possible incidence of the disease.
Total of 429 (219 NAFLD and 210 control) subjects were conveniently selected for study during the period of 9 months. Diagnosis of non-alcoholic fatty liver disease was done by liver imaging and based on liver enzymes. Assessment of metabolic syndrome was done by International Diabetic Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. All biochemical and hematological parameters and liver enzymes were estimated by using standard guideline. Mean comparison of quantitative data in different groups were performed using analysis of variance (one-way ANOVA). Risk estimation of NAFLD associated with each character was verified by Chi-square test.
There was significant high levels of body mass index (BMI), waist circumference (WC) and lipid profiles in NAFLD patients in comparison to control population (p < 0.001). Further, according to the NCEP ATP III criteria, 13.6% of NAFLD were present with MetS where risk estimate was significant (OR = 2.15). Whereas, other criteria (IDF) for MetS showed higher frequency (30.1%) with higher risk (OR = 29.75) for the presence of MetS in NAFLD patients. The change in triglycerides (TG) and HDL-C (high density lipoprotein cholesterol) was also statistically significant in different grades of NAFLD. High risk for NAFLD was associated with existing co-morbid conditions like cardiovascular risk patients (3.18 times) followed by obese patients (1.72 times) and Diabetes Mellitus patients (1.68 times) at a significant level.
The result of this study suggests that there is an increased prevalence of all the components of MetS and significant changes in biochemical markers in cases of NAFLD. Timely diagnosis would help in delaying its complications and co-morbidities.
非酒精性脂肪性肝病(NAFLD)与代谢综合征(MetS)相互关联且呈双向联系,它既是代谢综合征的病因,也是其后果。据估计,全球普通人群中有6.3%至33%患有该疾病,在伴有代谢合并症的人群中患病率甚至更高。因此,本研究旨在识别包括代谢成分和血液参数在内的各种风险因素,以预测该疾病的可能发病率。
在9个月的时间里,方便选取了429名受试者(219名NAFLD患者和210名对照者)进行研究。非酒精性脂肪性肝病的诊断通过肝脏成像并基于肝酶进行。代谢综合征的评估依据国际糖尿病联盟(IDF)和美国国家胆固醇教育计划成人治疗小组第三次报告(NCEP ATP III)的标准进行。所有生化、血液学参数和肝酶均按照标准指南进行测定。不同组定量数据的均值比较采用方差分析(单因素方差分析)。通过卡方检验验证与每个特征相关的NAFLD风险估计。
与对照组相比,NAFLD患者的体重指数(BMI)、腰围(WC)和血脂水平显著更高(p < 0.001)。此外,根据NCEP ATP III标准,13.6%的NAFLD患者伴有代谢综合征,风险估计具有显著性(OR = 2.15)。而代谢综合征的其他标准(IDF)显示,NAFLD患者中代谢综合征的发生率更高(30.1%),风险更高(OR = 29.75)。在不同分级的NAFLD中,甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)的变化也具有统计学显著性。NAFLD的高风险与现有合并症相关,如心血管疾病风险患者(3.18倍),其次是肥胖患者(1.72倍)和糖尿病患者(1.68倍),差异具有显著性。
本研究结果表明,NAFLD患者中代谢综合征所有成分的患病率均有所增加,生化标志物也有显著变化。及时诊断有助于延缓其并发症和合并症的发生。